Note: EPS may not be comparable

Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $8.8 million versus the consensus estimate of $7.53 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.